Robert M Eisele1, Ulf Neumann, Peter Neuhaus, Guido Schumacher. 1. Department of General, Visceral, and Transplantation Surgery, Charité Virchow-Clinic, Augustenburger Pl. 1, 13353, Berlin, Germany. robert_m.eisele@charite.de
Abstract
PURPOSE: This study was designed to determine the best approach to radiofrequency ablation (RFA) in the liver. METHODS: From a total of 41 procedures, 37 patients with 47 tumors were treated with RFA for metastatic disease. Indications included colorectal cancer (n=28, 68%), neuroendocrine tumors (n=2, 5%), gynecological primaries (n=4, 10%), pancreatic/duodenal cancer (n=2, 5%), and miscellaneous entities (n=5, 12%). Mean follow-up period was 18 (median, 18) months. All ways of approach to RFA were applied: percutaneous was chosen in 17 (41.5%), laparoscopic and hand-assisted laparoscopic in 5 (12.2%), and open surgical in 19 cases (46.3%), and in 10 cases, RFA was combined with hepatic resection. The average maximum tumor size was 2.3 (range, 0.8-6) cm, and the mean number of nodules treated per patient in a single session was 1.3 (range, 1-3). RESULTS: Overall survival was 59.5% at 2 years, recurrence-free 2-year survival was 12.6%, local tumor recurrence rate was 34%, and overall recurrence was 75.6%. Local tumor recurrence and disease-free survival were significantly improved in the open surgically treated patients compared with the percutaneous treatment group (15.8% [n=3] vs. 58.8% [n=10] and 11.5 vs. 7.9 months, p<0.01 [chi2 test] and p<0.05 [log-rank test], respectively). CONCLUSIONS: Open surgical approach is superior to percutaneous access for RFA in metastatic hepatic disease.
PURPOSE: This study was designed to determine the best approach to radiofrequency ablation (RFA) in the liver. METHODS: From a total of 41 procedures, 37 patients with 47 tumors were treated with RFA for metastatic disease. Indications included colorectal cancer (n=28, 68%), neuroendocrine tumors (n=2, 5%), gynecological primaries (n=4, 10%), pancreatic/duodenal cancer (n=2, 5%), and miscellaneous entities (n=5, 12%). Mean follow-up period was 18 (median, 18) months. All ways of approach to RFA were applied: percutaneous was chosen in 17 (41.5%), laparoscopic and hand-assisted laparoscopic in 5 (12.2%), and open surgical in 19 cases (46.3%), and in 10 cases, RFA was combined with hepatic resection. The average maximum tumor size was 2.3 (range, 0.8-6) cm, and the mean number of nodules treated per patient in a single session was 1.3 (range, 1-3). RESULTS: Overall survival was 59.5% at 2 years, recurrence-free 2-year survival was 12.6%, local tumor recurrence rate was 34%, and overall recurrence was 75.6%. Local tumor recurrence and disease-free survival were significantly improved in the open surgically treated patients compared with the percutaneous treatment group (15.8% [n=3] vs. 58.8% [n=10] and 11.5 vs. 7.9 months, p<0.01 [chi2 test] and p<0.05 [log-rank test], respectively). CONCLUSIONS: Open surgical approach is superior to percutaneous access for RFA in metastatic hepatic disease.
Authors: Alban L Denys; Thierry De Baere; Viseth Kuoch; Benoit Dupas; Patrick Chevallier; David C Madoff; Pierre Schnyder; Francesco Doenz Journal: Eur Radiol Date: 2003-08-27 Impact factor: 5.315
Authors: Guido Schumacher; Robert Eisele; Antonino Spinelli; Sven Christian Schmidt; Dietmar Jacob; Johann Pratschke; Peter Neuhaus Journal: J Laparoendosc Adv Surg Tech A Date: 2007-04 Impact factor: 1.878
Authors: T J White; S H Roy-Choudhury; D J Breen; J Cast; A Maraveyas; E F Smyth; J E Hartley; J R T Monson Journal: Dig Surg Date: 2004-09-13 Impact factor: 2.588
Authors: Andrea Frilling; Georgios C Sotiropoulos; Jun Li; Oskar Kornasiewicz; Ursula Plöckinger Journal: HPB (Oxford) Date: 2010-08 Impact factor: 3.647
Authors: Thomas J Vogl; Parviz Farshid; Nagy N N Naguib; Abbas Darvishi; Babak Bazrafshan; Emmanuel Mbalisike; Thorsten Burkhard; Stephan Zangos Journal: Radiol Med Date: 2014-06-04 Impact factor: 3.469
Authors: Karin Nielsen; Hester J Scheffer; José H Volders; Maurice J D L van der Vorst; Aukje A J M van Tilborg; Emile Fi Comans; E S M de Lange-de Klerk; Colin Sietses; Sybren Meijer; Martijn R Meijerink; M Petrousjka van den Tol Journal: World J Surg Date: 2016-08 Impact factor: 3.352
Authors: Klaas M Govaert; Charlotte S van Kessel; Martijn Lolkema; Theo J M Ruers; Inne H M Borel Rinkes Journal: Curr Colorectal Cancer Rep Date: 2012-03-17
Authors: Aukje A J M van Tilborg; Hester J Scheffer; Marcus C de Jong; Laurien G P H Vroomen; Karin Nielsen; Cornelis van Kuijk; Petrousjka M P van den Tol; Martijn R Meijerink Journal: Cardiovasc Intervent Radiol Date: 2016-07-07 Impact factor: 2.740